Rhythm Pharmaceuticals Ownership
| RYTM Stock | USD 56.69 0.87 1.51% |
Shares in Circulation | First Issued 2016-09-30 | Previous Quarter 61 M | Current Value 61 M | Avarage Shares Outstanding 40.6 M | Quarterly Volatility 16.6 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Rhythm |
Rhythm Stock Ownership Analysis
About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.75. Rhythm Pharmaceuticals recorded a loss per share of 4.32. The entity had not issued any dividends in recent years. Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Rhythm Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 140 people. To find out more about Rhythm Pharmaceuticals contact the company at 857 264 4280 or learn more at https://rhythmtx.com.Besides selling stocks to institutional investors, Rhythm Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Rhythm Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Rhythm Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Rhythm Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Rhythm Pharmaceuticals Insider Trades History
Less than 1% of Rhythm Pharmaceuticals are currently held by insiders. Unlike Rhythm Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Rhythm Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Rhythm Pharmaceuticals' insider trades
Rhythm Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Rhythm Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rhythm Pharmaceuticals backward and forwards among themselves. Rhythm Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Rhythm Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Driehaus Capital Management Llc | 2024-09-30 | 1.3 M | Geode Capital Management, Llc | 2024-09-30 | 1.3 M | Rock Springs Capital Management Lp | 2024-09-30 | 1.2 M | Alkeon Capital Management, Llc | 2024-09-30 | 1.2 M | Healthcare Of Ontario Pension Plan Trust Fund | 2024-09-30 | 1.1 M | Checkpoint Capital Lp | 2024-09-30 | 663.4 K | Commodore Capital Lp | 2024-09-30 | 650 K | Loomis, Sayles & Company Lp | 2024-09-30 | 636.6 K | Hood River Capital Management Llc | 2024-09-30 | 614.6 K | Primecap Management Company | 2024-09-30 | 7.2 M | Blackrock Inc | 2024-09-30 | 6.9 M |
Rhythm Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rhythm Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rhythm Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Rhythm Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rhythm Pharmaceuticals Outstanding Bonds
Rhythm Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Rhythm Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Rhythm bonds can be classified according to their maturity, which is the date when Rhythm Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Rhythm Pharmaceuticals Corporate Filings
F4 | 14th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 13th of February 2025 Other Reports | ViewVerify | |
8K | 10th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share | Quarterly Revenue Growth 0.478 | Return On Assets | Return On Equity |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.